Sourcebio International PLC
LSE:SBI
Intrinsic Value
SourceBio International Plc engages in the provision of laboratory services in healthcare, clinical, life science research, and biopharma industries. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SBI.
Sourcebio International PLC's market capitalization is 85.3m GBX.
SBI stock price is 115 GBX.
SBI.
SBI. Open DCF Valuation
SBI. Open Relative Valuation
SBI has upside potential of 83% compared to the average analyst price target.
Open Wall St Estimates
SBI has positive Net Income for the last twelve months.
SBI's ROE (Return on Equity) for the past 12 months is positive and is equal to 16%.
SBI's ROE (Return on Equity) has increased in the last 3 years from 9% to 16%.
SBI's ROIC (Return on Invested Capital) has decreased in the last 3 years from 33% to 27%.
SBI's Revenue has grown by an exceptional 33% over the past 12 months.
SBI has negative Net Debt. This means that the company has more cash and short-term investments (15m GBP) than debt (15m GBP).
SBI's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 27%.
SBI has positive Operating Income for the last twelve months.
SBI's short-term assets (24m GBP) exceed its short-term liabilties (13m GBP).
SBI has positive Gross Profit for the last twelve months.
SBI has positive Free Cash Flow for the last twelve months.
SBI's Revenue is forecast to fall at a rate of 19% per year over the next 3 years.
SBI's long-term assets (81m GBP) exceed its long-term liabilties (35m GBP).
SBI's D/E (Debt to Equity) is very low and is equal to 0.32.
SBI's Altman Z-Score is very high and is equal to 3.72.
SBI has very high three-year average ROIC (Return on Invested Capital): 47%. The company is very efficient at using invested capital to generate operating income.
SBI has negative three-year average ROE (Return on Equity): -26%. The company is not efficient at transforming stockholders' equity into net income.
SBI earns more than enough operating income (16m GBP) to safely cover interest payments on its debt (73k GBP).
Fundamental Analysis
Sourcebio International PLC
Balance Sheet Decomposition
Sourcebio International PLC
| Current Assets | 24.4m |
| Cash & Short-Term Investments | 15.2m |
| Receivables | 7.5m |
| Other Current Assets | 1.6m |
| Non-Current Assets | 56.3m |
| PP&E | 22.1m |
| Intangibles | 34.2m |
| Current Liabilities | 12.8m |
| Accounts Payable | 4.1m |
| Accrued Liabilities | 1.4m |
| Other Current Liabilities | 7.3m |
| Non-Current Liabilities | 21.9m |
| Long-Term Debt | 14.9m |
| Other Non-Current Liabilities | 7m |
Earnings Waterfall
Sourcebio International PLC
|
Revenue
|
103.2m
GBP
|
|
Cost of Revenue
|
-65.9m
GBP
|
|
Gross Profit
|
37.3m
GBP
|
|
Operating Expenses
|
-21m
GBP
|
|
Operating Income
|
16.3m
GBP
|
|
Other Expenses
|
-9.6m
GBP
|
|
Net Income
|
6.7m
GBP
|
Free Cash Flow Analysis
Sourcebio International PLC
SBI Profitability Score
Profitability Due Diligence
Sourcebio International PLC's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Sourcebio International PLC's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
SBI Solvency Score
Solvency Due Diligence
Sourcebio International PLC's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Sourcebio International PLC's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SBI Price Targets Summary
Sourcebio International PLC
According to Wall Street analysts, the average 1-year price target for
SBI
is 210 GBX
.
Shareholder Return
SBI Price
Sourcebio International PLC
| Average Annual Return | 8.77% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -59% |
| Market Capitalization | 85.3m GBX |
| Shares Outstanding | 68 201 696 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sourcebio International PLC
Country
Industry
Market Cap
Dividend Yield
Description
SourceBio International Plc engages in the provision of laboratory services in healthcare, clinical, life science research, and biopharma industries. The company is headquartered in Nottingham, Nottinghamshire. The company went IPO on 2020-10-29. The firm operates through four business segments: Infectious Disease Testing, Healthcare Diagnostics, Genomics and Stability Storage. Its Infectious Disease Testing segment offers COVID-19 antigen reverse transcription-polymerase chain reaction (RT-PCR) testing services to the national health service (NHS), private healthcare providers and private industry. Its Healthcare Diagnostics segment offers histopathology and clinical diagnostic services for the NHS and private healthcare across the United Kingdom and Ireland. Its Genomics segment offers deoxyribonucleic acid (DNA) sequencing services for pharmaceutical and biotechnology companies, academia, contract research organizations (CROs) and other research groups in the United Kingdom, Europe and North America. Its Stability Storage segment offers shelf-life testing services and equipment for pharmaceutical companies and others.
You don't have any saved screeners yet
